Hematology, Transfusion and Cell Therapy: Review Article

hematol transfus cell ther.
2 0 2 1;4 3(1):65–86
Hematology, Transfusion and Cell Therapy
www.htct.com.br
Review article
A review of hematopoietic stem cell

transplantation for autoimmune diseases: multiple
sclerosis, systemic sclerosis and Crohn’s disease.
Position paper of the Brazilian Society of Bone
Marrow Transplantation
Maria Carolina Oliveira a , Juliana Bernardes Elias a , Daniela Aparecida de Moraes a ,

Belinda Pinto Simões a , Morgani Rodrigues b , Andreza Alice Feitosa Ribeiro b ,
Lilian Piron-Ruiz c , Milton Arthur Ruiz c , Nelson Hamerschlak b,∗
a Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil
b Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
c Associação Portuguesa de Beneficência de São José do Rio Preto, São José do Rio Preto, SP, Brazil
a r t i c l e i n f o a b s t r a c t
Article history: Autoimmune diseases are an important field for the development of bone marrow trans-
Received 4 January 2020 plantation, or hematopoietic stem cell transplantation. In Europe alone, almost 3000
Accepted 23 March 2020 procedures have been registered so far. The Brazilian Society for Bone Marrow Transplanta-
Available online 29 April 2020 tion (Sociedade Brasileira de Transplantes de Medula Óssea) organized consensus meetings
for the Autoimmune Diseases Group, to review the available literature on hematopoietic
Keywords: stem cell transplantation for autoimmune diseases, aiming to gather data that sup-
Multiple sclerosis port the procedure for these patients. Three autoimmune diseases for which there are
Crohn disease evidence-based indications for hematopoietic stem cell transplantation are multiple sclero-
Systemic scleroderma sis, systemic sclerosis and Crohn’s disease. The professional stem cell transplant societies
Diffuse scleroderma in America, Europe and Brazil (Sociedade Brasileira de Transplantes de Medula Óssea) cur-
Bone marrow transplantation rently consider hematopoietic stem cell transplantation as a therapeutic modality for these
three autoimmune diseases. This article reviews the evidence available.
© 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
(HSCT). The European Society for Blood and Marrow Trans-

Introduction plantation (EBMT) recently published an update of transplant
indications for autoimmune diseases, with a total of 2809
Autoimmune diseases have become an important field for
cases registered at that point. The cases are summarized in
the development of hematopoietic stem cell transplantation
Table 1.1
∗
Corresponding author at: Unidade de Transplante de Medula Óssea do Hospital Israelita Albert Einstein, Av. Albert Einstein, 627/520, São
Paulo, SP CEP: 05652-900, Brazil.
E-mail address: [email protected] (N. Hamerschlak).
https://doi.org/10.1016/j.htct.2020.03.002
2531-1379/© 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
66 hematol transfus cell ther. 2 0 2 1;4 3(1):65–86
immune system.10,14 The purpose of HSCT in autoimmune

Table 1 – Hematopoietic stem cell transplants for
autoimmune diseases according to the European Society diseases is to promote immune depletion, eliminate autoreac-
for Blood and Marrow Transplantation (EBMT).1 tive lymphocytes, and to reprogramme the immune system,
Autoimmune diseases n
leading to the reestablishment of immune tolerance and,
thereby, prolonged disease control.15
Multiple sclerosis Total: 1415 The Brazilian Society for Bone Marrow Transplantation
Connective tissue diseases Total: 771
(Sociedade Brasileira de Transplantes de Medula Óssea,
Systemic sclerosis 609
SBMTO) organized consensus meetings for the Autoimmune
Systemic lupus erythematosus 110
Polymyositis-dermatomyositis 17 Diseases Group, to review the available literature on HSCT for
Sjogren’s syndrome 4 autoimmune diseases, aiming to gather evidence that support
Antiphospholipid syndrome 6 the procedure for these patients. Three of the most important
Other connective tissue diseases 25 indications for HSCT, sufficiently evidence-based, are multiple
Rheumatoid arthritis (inflammatory arthritis) Total: 190 sclerosis (MS), systemic sclerosis (SSc) and Crohn’s disease.
Inflammatory bowel diseases Total: 200 As the following sections show, the American Society for
Crohn’s disease 179 Transplantation and Cellular Therapy (ASTCT), the European
Celiac disease 16 Society (EBMT), and the Brazilian SBMTO currently consider
Ulcerative colitis 2
HSCT as part of the already consolidated treatment proce-
Other inflammatory bowel diseases 3
dures for these three autoimmune diseases, outside research
Hematologic diseases Total: 56
Immune thrombocytopenia 28 trial settings.
Autoimmune hemolytic anemia 13
Evans’ syndrome 10
Other hematological diseases 5 Multiple sclerosis
Vasculitis Total: 48
Granulomatous and polyangiitis 10 Multiple sclerosis (MS) is a demyelinating chronic inflamma-
Behcet’s disease 9 tory disease of the central nervous system that mainly affects
Takayasu’s arteritis 3 young adults, and has heterogeneous clinical and pathologi-
Polyarteritis 3 cal characteristics resulting from different pathways of tissue
Churg Strauss syndrome 2
injury.16 Inflammation, demyelination, and axonal degenera-
Other vasculitis 21
tion are the main pathological mechanisms that cause clinical
Other neurological diseases Total: 109 manifestations.17 However, the cause of MS is unknown18,19
Insulin dependent diabetes Total: 20
and it is considered an incurable disease. The most widely
Other autoimmune diseases Total: 23
accepted theory is that MS begins as an autoimmune inflam-
Total 2809 matory reaction mediated by autoreactive lymphocytes.16,20
Microglia activation and chronic neurodegeneration occur
later. Regardless of the immune pattern of early demyelina-
Although autologous HSCT (AHSCT) has been used world- tion, analyzes of active lesions over time suggest that there is
wide to treat autoimmune diseases, with slightly different a single immuno-effector mechanism in each person.21
approaches among centers, the main strategy remains sim- MS begins at the median age of 23.5 years, and mean age
ilar. Briefly, the procedure consists of a first phase, when of 30 years.22 Mortality among patients with MS is not much
autologous hematopoietic stem cells are harvested and cryop- different from the general population, but neurological deficits
reserved, and a second phase, including conditioning regimen progress in all patients. It is expected that in 15 years from
and stem cell infusion. Patients undergo mobilization of diagnosis, 50% of patients will need help walking, and after 25
hematopoietic stem cells from the bone marrow to peripheral years, most cannot walk anymore.23,24
blood through a combination of drugs including filgrastim (a MS symptoms are non-specific and may include pares-
granulocyte colony stimulating factor, G-CSF), followed by cell thesias and paresis due to transverse myelitis, ataxia due to
harvesting by leukapheresis and cryopreservation. Most trans- cerebellar injury, tremor, monocular visual loss due to optic
plant centers use 2–4 g/m2 cyclophosphamide and granulocyte neuritis, double vision due to brainstem dysfunction, fatigue
colony-stimulating factor (G-CSF) for subsequent collection of and sphincter changes. If there is a relapse episode, the func-
hematopoietic progenitor cells.2–13 The scheme allows for col- tional disability scale score used in neurological examination
lection of more cells than the use of G-CSF as a single agent, increases, indicating worsening. During remission, the patient
and very few events of mobilization failure are described. remains stable within his or her disability score. Numerous
Additionally, the administered cyclophosphamide promotes scales have been described to evaluate MS, the most used
initial control of disease activity, contributing to the therapeu- being the Expanded Disability Status Scale (EDSS), described
tic effect of the transplant procedure.10,11,13 by Kurtzke.25
At the second phase of HSCT, patients receive immunoab- MS is classified in three clinical types, which receive differ-
lative doses of a lymphoablative conditioning regimen that ent treatment approaches. The first is the relapsing remitting
may include chemotherapeutic agents, immunotherapeutic type (RRMS), resulting from inflammatory multifocal lesions
agents and/or irradiation, followed by autologous cell infusion. that cause clinical recurrence and activity of detectable lesions
A period of aplasia follows, after which there is engraftment on magnetic resonance imaging (increase or appearance of
and reconstitution of a tolerant and no longer self-reactive new lesions on hyperintense T2 or increase of gadolinium on
hematol transfus cell ther. 2 0 2 1;4 3(1):65–86 67
T1 lesions). It manifests with episodic relapses followed by use of HSCT to treat MS: there are 8 retrospective studies
partial or total recovery from dysfunction, interspersed with and 6 single-arm clinical trials on AHSCT for MS, and only
remission periods of at least 30 days.23,24 2 randomized clinical trials focusing on the comparison of
After an average time of 10–15 years, the episodes become AHSCT versus disease-modifying therapies for MS. There are
less frequent, followed by less evident recovery, with accumu- also 3 meta-analysis and systematic reviews and one position
lation of sequelae and gradual worsening of the neurological paper.6,9,10,39,49–57
picture that is typical of the secondary progressive form These studies together support the efficacy of AHSCT in
(SPMS). This is characterized by neurodegeneration, but may patients with relapsing form of MS. Although they differed in
still have superimposed inflammatory activity.23,24 design, population, conditioning protocol and only two were
The third clinical type of MS, the primary progressive MS randomized with a control group, many patients experience
(PPMS), occur in about 10–15% of patients, at the mean age disease activity control for a long time. The largest retrospec-
onset of approximately 40 years, and occurs equally in males tive study was a review from the CIBMTR/EBMT register in
and females. It is characterized by progressive accumulation of 2017 that analyzed 281 patients.53 Overall progression-free
disability from disease onset. Can occur occasional plateaus, survival rate was 46%; among patients with RRMS or PRMS,
minor and temporary improvements but after all continues progression-free survival rates were 82% at 3 years and 73% at
progressing. The diagnosis is made based only on patient’s 5 years; OS at 5 years was 93%. Factors associated with neuro-
history. This “malignant form” or “aggressive form” of MS, is logic progression post AHCT was older age, progressive versus
characterized by rapidly progressive course, leading to signif- relapsing form of MS and more than two previous disease
icant disability, or even death, in multiple neurologic systems modifying therapies (DMTs).
in a relatively short time after disease onset.23,24 All the single-arm35,58–63 clinical trials demonstrated high
The worsening of symptoms is highly heterogeneous efficacy of AHSCT for RRMS or PRMS. The first reported was
among patients with MS. The extent of inflammatory activity by Burt et al., with 21 patients with RRMS conditioned with
affects MS prognosis substantially. Because of that, the goal of cyclophosphamide plus rabbit ATG/alemtuzumab, showing a
treatment approaches is the absence of disease activity clini- EDSS progression free survival at 3 years of 100% and EDSS
cally or at magnetic resonance imaging and the improvement improvements ≥1 in 81% and no change in 9.5%, OS of 100%.59
of disability or of the EDSS score. This is called “no evidence Recently Moore at al. reported 35 patients with RRMS and
of disease activity” (NEDA).26 SPMS in a phase 2 study conditioned with BEAM and horse
ATG showing a MS activity-free survival of 82% at one year
Conventional therapeutic approaches for multiple sclerosis 65% at 2 years and 60% at 3 years; looking at RRMS only the
MS activity-free survival was 90% at one year and 70% at 3
As of December 2017, the US Food and Drug Administration years.63
(FDA) has approved 15 drugs considered as capable of modify- Only two randomized controlled trials are available: in the
ing MS course: 5 interferon-beta preparations; two glatiramer ASTIMS study, Mancardy et al. compared AHSCT versus mitox-
acetate preparations; the monoclonal antibodies natalizumab, antrone; 9 out 21 were randomized to AHSCT.52 They were
alemtuzumab, daclizumab and ocrelizumab (the first B-cell conditioned with BEAM plus rabbit ATG. Over 4 years, the
targeted therapy); the chemotherapeutic agent mitoxantrone; median number of new T2-weighted MRI lesions was 2.5 in
and small molecule oral agents fingolimod, dimethyl fumarate the AHSCT versus 8 in the mitoxantrone group (p = 0.00016)
and teriflunomide. Dalfampridine (aminoperidine) has been and none of those who received AHSCT had new gadolinium-
approved as a therapy to treat and improve gait speed.21 How- enhanced MRI lesions, but 56% of those on mitoxantrone
ever, none of these are curative therapies. They are partially had at least 1 MRI lesion (p = 0.029); EDSS progression was
effective in reducing relapse rates and disease progression. 57% in AHSCT vs 48% in the mitoxantrone group (p = 0.50).
Furthermore, all disease-modifying therapies present safety The phase 3 MIST trial55 compared the efficacy of AHSCT
concerns, with the risk increasing over time. Better treat- versus DMTs. The conditioning was non-myeloablative, with
ment strategies are required for patients with relapsing MS, cyclophosphamide plus rabbit ATG and 110 patients were
for those who present inflammatory activity despite the treat- randomized 1:1. With a follow-up of up to 5 years, disabil-
ment used and for those with treatment side effects.27 ity worsening occurred in 5.8% AHSCT versus 66.7% of DMT
group. At 1 year, relapse occurred in 2% in the AHSCT and
Transplant in multiple sclerosis 68.2% in the DMT group 9; with p < 0.001 and at 5 years, relapse
occurred in 15.4% AHSCT vs 85.2% DMT group; no deaths or
Since the mid-1990s, with the first studies on animal models grade 4 toxicities related to transplantation were reported.
with subsequent clinical application, autologous transplan- A meta-analysis of AHSCT for MS evaluated the safety and
tation (AHSCT) has been an important tool in inducing an efficacy of transplant. Led by Somani at al., it evaluated 15
“immunotolerant” immune reconstitution.2,3 Thousands of studies including more than 764 transplanted patients. A pro-
transplants for treating MS have been performed world- portion of NEDA (no evidence of disease activity) was found
wide, with more than 700 evaluated in studies.6,28–46 Some in 2 years in 83% and in 5 years 67%; the transplant-related
studies showed progression-free survival of more than five mortality was estimated in 2.3%, the rate of EDDS progression
years,39,43 with superior neurological improvement in patients was 17.1% at 2 years and 23.3% at 5 years.54 Another interest-
with relapsing-remission type and in those with inflamma- ing study done by Sormani et al.64 evaluated a comparison of
tory activity observed on magnetic resonance imaging.43,47,48 NEDA status in studies of AHSCT (n = 66) with various conven-
Table 2 shows the results of the main studies focused on the tional e high-efficacy MS DMTs (n = 216). The use of AHSCT led
68
Table 2 – Results of studies on multiple sclerosis disease.
Site/year of Study design Comparisons Endpoints Inclusion N Transplant PFS/outcomes Relapse/ Non-relapse OS Follow-up
publication(ref) criteria/ regimen progression mortality
rate
Retrospective studies
Italy 201249 Retrospective None EDSS MS treated 74 BEAM + rabbit EDSS PFS at 30% for RRMS vs 2.7% 95.9% Median 4
case series progression previously (33 RRMS and ATG 5y 66% for all 10% for SPMS years (8
free-survival with DMT 41 SPMS) patients mo–10.5 yrs)
with severe RRMS EDSS
clinical PFS 5y 71%
course past
year (EDSS
worsen-
ing ≥ 1.0)
Swedish 201456 Retrospective None Relapse free MS treated 52 but BEAM + ATG At 5y: EDSS At 5 years, 4 Zero TRM 100% Mean 4.0
case series survival, MRI previously analyzed 41 in 41 and Cy PFS 77%; patients had years (1–9 yrs)
hematol transfus cell ther. 2 0 2 1;4 3(1):65–86

event free with DMT (40 RRMS, 5 (200 mg/kg) + clinical clinical relapse, 5
survival, SPMS, 2 ATG in 7 relapse free had MRI activity,
EDSS PFS and PPMS,) survival 87%; 8 had EDSS
DFS MRI progression
event-free
survival 85%
and DFS: 68%
Northwest- Retrospective None Time to EDSS RRMS failed 151 but 145 CY EDSS The proportion Zero TRM 99.3% (1 2,5 years (6
ern/Chicago case series improvement DMT, with 2 analyzed 200 mg/kg + improved of patients with death due month–5 yrs)
201555 and time to or more alentuzumab 50% at 2 a 1.0 or greater hypertensive
EDSS treated 20 mg or years, 64% at change in EDSS cardiovascu-
worsening relapses or 1 rabbit ATG 4 years score was 10% in lar
both at least treated 6 mg/kg 19 of 112 patients disease)
1.0 point relapse with Relapse-free with an
Gd lesion at a survival was indication of
separate 89% at 2 years progression at 1
time/RRMS and 80% at 4 year and
123, SPMS 28 years;
11% in 9 of 82 for
PFS was 92% progression at 2
at 2 years and years; and 11% in
87% at 4 years 7 of 64 for
and disease progression at 3
activity–free years;
survival was
80% and 68% and 8% in 3 of 36
respectively for progression
at 4 years; and
5% in 4 of 27 for
progression at 5
years.
Table 2 – (Continued)
rate
CIBMTR/EBMT Retrospective None PFS Data base of RRMS failed High Overall PFS 2.8% 93% at 5 years Median 6.6
Review53 registry AHSCT for DMT, with 2 intensity in was 46%; yrs
review MS/46 RRMS, or more 53/281 among
186 SPMS, 32 treated (18.9%); patients with
PPMS, 17 relapses or 1 intermediate RRMs/PRMS
PRMS treated intensity in PFS was 82%
relapse with 49/281 at 3 years and
Gd lesion at a (17.4%); low EDSS PFS 73%
separate intensity in at 5 years
time/RRMS 49/281
123, SPMS 28 (17.4%).

Czech Republic Retrospective None Reported All patients Data base of BEAM in 26 PFS at 3 years Median annual Zero 96.1% (1 Median 66
201039 case series efficacy of treated with AHSCT for and 70.8% and relapse rate death due to months
AHSCT AHSCT 10 MS/46 RRMS, BEAM + ATG 29.2% at 6 within the year glioblastoma (11–132)
experience in years 186 SPMS, 32 in 16 years before ASCT was multiforme at
MS PPMS, 17 2, while the 60 months of
11 RRMS, 15 PRMS median annual follow-up)
SPMS relapse rate was
0 within the first
2 years after
ASCT
Spain 201757 Retrospective None Reported RRMS/SPMS 31 BEAM + rabbit 100% of RRMs 32.3% (10) had at Zero 96.7% (1 Median 8.4
case series toxicity and under ATG were free of least one relapse death 13 years (2–16)
the long-term treatment disability at 6 post-AHSCT; 6 in years after
efficacy of with one of months; and the RRMS group transplant
AHSCT the 60% (27.2%) and 4 in from
MS-approved achieving the SPMS group aspiration
drugs for sustained (44.4%). 7 (22.6%) pneumonia
more than 1 disability experienced after
year, who recovery at 6 progression of progressing
experienced months; disability, all and reaching
one or more 22% of SPMS within SP form. an EDSS of
relapses in were free of 9.5.)
the previous disability at 6
year and months; and
worsening of 10%
at least 1 achieving
point in sustained
disability disability
(EDSS) recovery at 6
months
22 RRMS, 9
SPMS
69
70
rate
Single-arm prospective study

Russia 201558 Single arm None Safety and All patients 99 Reduced EFS for the 16.7% at 8 years. Zero 100% Median 48.9
clinical trial efficacy treated with intensity whole group months
(treatment AHSCT 6 (43 RRMS, 56 conditioning was 80%. In
response) years: EDSS SPMS, 18 regimen the group
1.5–8.0, ±Gd PPMS, 3 based on with RRMS,
lesions, and PRMS) BEAM EFS was
no treatment 83.3% and in
with the group
interferons or with

immunosup- progressive
pressive course 75.5%
agents within
3 months 92% EDSS PFS
before 5 years
enrollment
Northwest- Single arm None EDSS PFS and RRMS with 2 21 Cychophos- 100% EDSS 5 patients (24%) Zero 100% Mean 3.1
ern/Chicago clinical trial reversal of steroid phamide + PFS 3 years relapsed but years (1.5–10)
200959 neurologic treated (21 RRMS) alemtuzumab achieved
disability relapses in /rabbit ATG remission after
previous 12 further immuno-
month. suppression
After a mean of
37 months (range
24–48 months),
all patients were
free from
progression (no
deterioration in
EDSS score), and
16 were free of
relapses
Canada 201662 Single arm None MS Disease 24 Cyclophos- 70% PFS 3 No clinical 4.2% 95% Median 6.1
clinical trial activity-free activity phamide/ years relapse year (±2.5)
survival despite 1 year (12 RRMS, 12 busulfan
(absence of of DMT. SPMS)
clinical
relapse, new
MRI lesion or
progression
of EDSS)
rate
HALT-MS 2015, Single arm None Time to RRMS with 24 BEAM + rabbit 70% NEDA 5 Two participants Zero 87.5% Median 4.9
201760,61 clinical trial treatment failure of (24 RRMS) ATG years, 91% had disease year (6–12)
failure (death DMTs during EDSS PFS progression and
or MS the prior 18 died at .2.5 years
activity) months and .3.5 years
after AHSCT; a
third participant
also had disease
progression at 15
months and died
at 4.5 years

post-HCT
Of 24 patients 7
did not maintain
EFS by close of
follow-up by an
increase in EDSS
0.5 (n = 2), clinical
relapse (n = 3) or
development of
new MRI lesions
(n = 2)
Australia Single arm None EFS (NEDA) RRMS with at 35 BEAM + horse 60% NEDA 3 Clinical relapses Zero 100% Median 6.9
201863 clinical trial least 1 (20 RRMS, 15 ATG year occurred in 3 year (0.7–21.6)
relapse or SPMS) patients at 12, 13
one new MRI and 14 months,
lesion in the respectively after
past year AHSCT
despite
DMT/SPMS
worsening
with at least 1
MRI lesion in
the past year.
Randomized study
ASTIMS 201552 Phase II, AHSCT vs Cumulative Worsening in 21 (9 to BEAM + ATG New T2 lesion EDSS progression Zero 100% 4 years
AHSCT vs mitox- number of EDSS and one AHSCT) MRI: 2.5 was 57% in
mitoxantrone antrone new T2 lesion or more MRI AHSCT vs 8 AHSCT vs 48% in
MRI 4 years lesion last 7 RRMS, 13 mitoxantrone the
after random- year despite SPMS, 1 PPMS 4 years mitoxantrone
ization DMTs (p = 0.5)
71
72
rate
MIST 201855 Phase3 AHSCT vs 6-Month At least 2 110 (55 Cyclophos- At 1 year, 15.4% AHSCT vs Zero 100% Up to 5 years

AHSCT vs DMT worsening clinical AHSCT) phamide + mean EDSS 85.3% of relapse
conventional EDSS ≥ 1.0 relapse, or rabbit ATG improved at 5 years.
DMT after one one relapse 110 RRMS from 3.38% to Disability
year’s in MRI lesion 2.36% with worsening occur
post-AHSCT at different AHSCT and in 5.8% AHSCT vs
or DMT time in the worsened 66.7% DMT
treatment last year from 3.31 to group; median
despite DMT 3.98 with time to pression
DMTs. At 1 24 months in the
year, mean DMT.
T2 lesion
volume on
MRI
decreased in
the AHSCT,
but increased
in The DMT
group.
N: number of enrolled subjects; PFS: progression-free survival; OS: overall survival; EDSS: Expanded Disability Status Scale; TRM: transplant-related mortality; FU: follow-up; AHSCT: autologous
hematopoietic stem cell transplantation; SPMS: secondary progressive MS; PPMS: primary progressive MS; PRMS: progressive relapsing; DMT: disease modifying treatment; NEDA: no evidence of
disease activity (absence of relapse, disability worsening on the EDSS or MRI lesion activity); MRI: magnetic resonance imaging; Gd: gadolinium-enhanced lesion on MRI.
Box 1: Indications for autologousa hematopoietic stem Box 2: Contraindications to hematopoietic stem cell
cell transplantation (HSCT) in multiple sclerosis (MS). transplantation in multiple sclerosis.
Patients under 60 years old who are not responsive to the • Advanced disease and no inflammatory activity
current first line standard therapy and who present EDDS • EDSS > 6.0
between 3 and 6 • Renal impairment: serum creatinine > 2 mg/dL
(177 ␮mol/L) or creatinine clearance (CrCL) < 50.
Patients with inflammatory activity in the forms:
• Liver dysfunction: Frank cirrhosis. Other condition
- relapsing-remitting: IB;
related to liver dysfunction (hepatitis, alcohol abuse,
- secondary progressive with inflammatory activity
hepatic steatosis and iron overload) need consultation
(clinical and imaging): IIB;
with a hepatologist to contraindication
- primary progressive with inflammatory activity (clinical
• Cardiac disease: left ventricular ejection fraction (LVEF)
and imaging): IIB
≤40% for BEAM condition and LVEF ≤50% using
Patients with the “malignant” form of multiple sclerosis chemotherapy regimens with known cardiac toxicity (e.g.,
who developed severe disability in the previous year: IIB cyclophosphamide) or uncontrolled coronary artery
disease or uncontrolled arrhythmias.
EDSS: Expanded Disability Status Scale. • Pulmonary dysfunction: corrected DLCO < 50%
a Allogeneic HSCT is not recommended for any category
• Poorly controlled chronic diseases (diabetes,
of MS. hypertension)
• Pregnancy
• HIV positivity
to NEDA rates of 78–83% at 2 years and 60–68% at 5 years. On
• History of previous malignancy
the other hand, DMTs lead to reported NEDA rates of 13–46%
• Psychiatric disorders
at 2 years.
Transplant-related mortality (TRM) has improved over the EDSS: Expanded Disability Status Scale.
past 20 years.14,54 The initial reports described TRM as high as
9.5% (37, revised in 65), which later decreased to 1.3%, accord-
ing to EBMT data.6,9 The incorporation of less myeloablative vasculopathy.71,72 The disease usually begins with vascular
regimens, center experience and center accreditation have hyperreactivity and endothelial activation, which, associ-
contributed to the improved outcomes.8,59,65–68 ated with inflammatory phenomena, promotes progressive
Recently the American Society of Bone Marrow tissue damage and fibrosis.73 The etiology, still not com-
Transplantation50 has conducted a comprehensive litera- pletely understood, includes a susceptible genetic background
ture review, including many of the papers already discussed associated with environmental stimuli, which promote
here, and recommended autologous HSCT as “standard of immune dysregulation and, as a consequence, injury to
care, clinical evidence available” for treatment-refractory tissues.71,73
relapsing MS. Patients with severe and progressive forms of SSc have
reduced quality of life and mortality rates that can reach 50%
Guidelines for transplantation in multiple sclerosis in five years and 70% in 10 years.74 Cardiopulmonary dys-
function is the leading cause of death, especially in patients
Considering the results presented above, HSCT can be consid- with interstitial lung disease and pulmonary hypertension.71
ered for patients with relapsing-remitting form of MS, with A meta-analysis has shown that the mortality of patients with
EDSS less than 6, who have not responded to conventional SSc has not decreased in the past 40 years, despite new avail-
treatment or progressive MS with superimposed activity. Espe- able treatment options.75
cially if disease activity continues despite treatment with
high-efficacy DMTs and worsening disability. The treatment Clinical presentation
for other MS types should follow the guidelines proposed by
SBMTO previously,69 shown in Box 1 and Box 2, and using
Skin involvement is a hallmark of SSc, and its extent
the same reduced-intensity conditioning with cyclophos-
enables clinical classification into three subtypes: limited, dif-
phamide (200 mg/kg) and rabbit anti-thymocyte (4.5 mg/kg).
fuse and sine scleroderma (without cutaneous involvement).
Intensive vigilance should be maintained for short and long-
The extent of skin involvement correlates with disease
term post-transplant complications, especially fever, deep
presentation and severity. Patients with the diffuse form
vein thrombosis, pulmonary embolism, urinary tract infec-
of SSc suffer from interstitial lung disease, cardiac and
tions, falls, metabolic syndrome and coronary disease.65,70
renal involvement more frequently.72 This subtype tends
to progress faster and with greater severity, morbidity
Systemic sclerosis and mortality than other forms of the disease.72,76,77 On
the other hand, limited systemic sclerosis patients tend
Systemic sclerosis (SSc) is a chronic autoimmune disease char- to present pulmonary hypertension as a life-threatening
acterized by fibrosis of the skin and internal organs, and manifestation.
Conventional therapeutic approaches The exclusion criteria for HSCT to consider based on avail-
able studies are the following10,88,89 :
The management of patients with systemic sclerosis
(SSc) includes pharmacological and non-pharmacological • Age over 60 years;
approaches.78 Hand and extremity warming and protection • Current pregnancy;
against trauma, dietary and postural measures to reduce gas- • Inability to practice effective contraception;
troesophageal reflux and treatment of skin and digital ulcers • Inability to accept infertility as a possible consequence after
are recommended for most patients, given the high frequency transplantation;
of these manifestations.78 • Severe psychiatric disorder;
Conventional drug treatment is quite limited and inef- • Current acute or chronic infection;
fective in controlling the progression of the disease. There • Previous malignancy, except localized and treated cervical
are no drugs that treat SSc globally, and therapeutic strate- and thyroid cancer;
gies are often organ or manifestation-directed. Currently, • Major organ dysfunction, as follows:
international rheumatology societies have developed rec- • Liver – increased alanine aminotransferase (ALT) or
ommendations for the treatment of patients with SSc, aspartate aminotransferase (AST), over three times the
always according to individual manifestations.78,79 Random- normal range; or increased serum bilirubin levels, over
ized clinical studies have investigated synthetic and biological three times the normal range, except when Gilbert’s syn-
immunomodulatory agents, showing modest benefits and no drome present;
repercussions on disease-related mortality, with exception of • Kidneys – creatinine clearance below 40 ml/min; or crea-
angiotensin-converting enzyme (ACE) inhibitors, which in the tinine levels above 2 mg/dL;
past significantly decreased the mortality of patients with • Lungs – forced vital capacity or hemoglobin-adjusted CO
scleroderma renal crises.59,78 diffusion below 40% of predicted;
Interstitial lung disease is a severe manifestation of • Heart – left ventricular ejection fraction below 50%, con-
SSc and the leading cause of death in this disease. The strictive pericarditis, ventricular arrhythmias, extensive
available treatments have modest and short-lived success myocardial fibrosis, systolic pulmonary artery pressure
rates on the control of interstitial lung disease.71,78–81 Best greater than 40 mmHg or mean pulmonary artery pres-
outcomes are described for cyclophosphamide and mycophe- sure greater than 25 mmHg, evidence of ventricular
nolate mofetil, with short-term benefit when compared with diastolic dysfunction, septal dyssynergia.
placebo.82,83 More recently, rituximab, tocilizumab, nintedanib
and pirfenidone, among other therapeutic agents, have been Historically, the initial studies were important to establish
investigated with promising results, yet to be confirmed.84–87 recommendations and guide currently adopted procedures.
Isolated diffuse skin involvement, when severe and progres- Phase I/II studies showed that autologous HSCT (AHSCT)
sive, is also associated with high mortality rates and poor improves skin involvement and at least stabilizes the pul-
quality of life, with outcomes comparable to those of patients monary condition (Table 3).11,12,91–96 These studies also
with visceral involvement.86 Thus, systemic immunosuppres- evidenced the importance of a proper heart assessment as
sion is recommended for selected cases.87 a strategy to decrease transplant-related mortality. Cardiac
dysfunctions that occur during transplantation accounted
for many of the transplant-related deaths described in the
initial studies.97 Currently, there are detailed cardiac assess-
ment recommendations,98 aimed at identifying patients with
Hematopoietic stem cell transplantation previous cardiac lesions and, therefore, at a higher risk of car-
diotoxicity.
In the past years 20 years, AHSCT has been indicated as treat- The three randomized studies more recently published
ment for patients with severe and rapidly progressive SSc.10 show that HSCT surpasses conventional treatment in SSc
According to data from international transplant registries, the patients, promoting longer overall survival, longer disease-
number of transplanted patients per year has progressively free survival and higher quality of life (Table 3).88,99,100 These
increased, reflecting the good outcomes of this therapeutic results are essential to convince the community about the
approach.14 efficacy of HSCT. In fact, since 2017, AHSCT has been rec-
The most recently adopted indication criteria for trans- ommended by the European League Against Rheumatism
plantation are the following10,88,89 : (EULAR) guidelines, for patients with SSc at risk of organ
failure.78
• An established diagnosis of systemic sclerosis, according to Treatment protocols have been refined and incorporated
the 2013 ACR/EULAR classification criteria90 . into the routine of several transplant centers. However, a few
• Patients with diffuse form of the disease, with a minimum points of debate still remain. There is still no consensus among
modified Rodnan’s score of 16, and worsening by at least 25% centers whether to adopt graft selection or to use non-selected
in the last 6 months, under immunosuppressive treatment. grafts. While CD34+ graft selection may prevent reinfusion
• Patients with interstitial lung involvement with a decline of autoreactive cells during transplant and potential disease
in predicted forced vital capacity (FVC) or carbon monoxide reactivation, it adds costs to the procedure and increases
(CO) diffusion percentages greater than 10% in the preced- the risk of contamination and cell death. A retrospective
ing 6 months, while under immunosuppressive treatment. study from the European Blood and Marrow Transplant Group
Table 3 – Results of studies on systemic sclerosis disease.
Site/year of Study design Comparisons Endpoints Inclusion N Transplant PFS Relapse/ Non-relapse OS
publication(ref) criteria regimen progression mortality
rate
Single-arm studies
Europe + USA Phase I/II None, single Feasibility, Diffuse SSc or 41 (37 Multiple, 46% at 4y 23% (7/30) at 17% (7/41) 73% at 4y
multicenter/200191 arm mortality and limited SSC transplanted) most CY 4y
preliminary with 150–200 mg/kg ±
response to interstitial ATG/alemtuzu-
treatment lung disease
or pulmonary mab and/or
hypertension TBI
France Phase I/II None, single Feasibility, Early (<4y) 12 (11 CY or 45% at mean 50% (5/10) at 9% (1/11) 64% at mean

multicenter/200293 arm tolerance and diffuse SSc transplanted) Melphalan 18 months mean 18 18 months FU
efficacy plus visceral CD34+ months FU
involvement selected graft
USA Pilot study None, single Safety and Early (<3y) 19 TBI 63% at mean 25% (4/16) at 16% (3/19) 79% at mean
multicenter/2002104 arm potential diffuse SSc 800 cGy + CY 15 months mean 15 15 months
efficacy plus visceral 120 mg/kg + months
involvement 90 mg/kg
or progressive eATG
interstitial CD34+
lung disease selected graft
Europe Retrospective All studies Safety and Early (<3y) 57 Multiple, 58% at 5y 48% at 5y 8.7% (5/57) 72% at 5y
multicenter/200494 analysis of were non- efficacy diffuse SSc or most CY
phase I and II comparative, progressive 150–200 mg/kg ±
studies single arm interstitial ATG/alemtuzumab
lung disease and/or TBI
USA Phase II None, single Safety and Early (<4y) 34 TBI 64% at 5y 15% (4/26) at 23% (8/34) 64% at 5y
multicenter/200795 arm efficacy diffuse SSc 800 cGy + CY 5y
plus visceral 120 mg/kg +
involvement 90 mg/kg
or progressive eATG
interstitial CD34+
lung disease selected graft
USA Phase I None, single Safety Diffuse SSc 10 CY 70% at mean 22% (2/9) at Zero 90% at mean
(Chicago)/200796 arm (toxicity and plus visceral 200 mg/kg + 25.5 months mean 25.5 25.5 months
transplant- involvement 7.5 mg/kg months
related or pulmonary rATG
mortality) disease Unselected
regardless of graft
skin
involvement
75
76
rate
Germany Retrospective None, single Safety and CY inefficacy 26 CY 53% at 3y 39% (9/23) at 4% (1/26) 74% at 3y
(Berlin)/201212 analysis arm efficacy or diffuse SSc 200 mg/kg + 3y
with bad 40 mg/kg
prognosis rATG*
CD34+
selected graft

EUA (Chicago) and Retrospective None, single Efficacy and Diffuse SSc 90 CY 70% at 5y 15% (13/85) at 6% (5/90) 78% at 5y
Brazil (Ribeirão analysis arm use of cardiac plus visceral 200 mg/kg + 5y
Preto)/201389 screening involvement 4.5-6.5 mg/kg
or pulmonary rATG
disease No graft
regardless of selection
skin
involvement
Italy Phase II HSCT vs Safety and Diffuse SSc 18 HSCT + 36 CY Not available. Not available. 5.6% (1/18) in 89% in HSCT
(Milan)/201711 historical efficacy with SSc controls 200 mg/kg + Significantly Significantly HSCT group. group and
cohort progression 7.5 mg/kg higher PFS in lower disease Not available 39% in SSc
of skin or of rATG HSCT than in progression for SSc controls, at 5y
visceral CD34+ SSc control in HSCT than control group
disease selected graft group in SSc control
group
Europe Prospective None, single Safety and Transplanted 80 In 76 82% at 2y 13% (11/85) in 6.25% (5/80) 90% in 2y
(multicenter) and observational group efficacy patients with patients: 2y
Brazil (Ribeirão progressive median CY
Preto)/2020102 SSc with data 200 mg/kg + rATG
registered to In 4 patients:
the EBMT Thiotepa
database 10 mg/kg + CY
100 mg/kg + rATG
CD34+
selection in
44%
rate
Randomized studies
ASSIST (Chicago, Phase II, open HSCT versus Improvement Diffuse SSc 19 (10 HSCT CY 100% in HSCT Zero in HSCT Zero in HSCT 100% at mean
USA)/201199 label, 6 monthly IV in skin score plus visceral arm and 9 CY 200 mg/kg + arm (10 arm and CY arms, 2.6y of FU
randomized CY pulses or lung involvement arm) 6.5 mg/kg patients) and and 89% (8/9) at mean 2.6y
1:1 function in 12 or progressive rATG 11% in CY in CY arm at of FU
Patient months of interstitial Unselected arm, at 12 12 months of
cross-over follow-up lung disease graft months FU. FU.
from CY to 7 patients
HSCT arm from CY arm 12% (2/17) in
allowed at 12 crossed over all

months of FU. to HSCT at 12 transplanted
months FU patients
and all (original and
improved. crossed-over)
At 2.6y of at mean 2.6y
mean FU of FU
after HSCT,
PFS was 88%
ASTIS (Europe Phase III, HSCT versus Progression/ Early (<4y) 156 (79 HSCT CY 77% in HSCT 11% (7/66) in 10% (8/79) in 80% in HSCT
multicenter)/201488 open label, 12 monthly relapse-free diffuse SSc arm and 77 200 mg/kg + arm and 65% HSCT arm HSCT arm arm and 65%
randomized CY pulses survival, plus major CY arm) 7.5 mg/kg in CY arm, at and 35% and zero in in CY arm at
1:1 toxicity, organ rATG 4y FY (20/57) in CY CY arm at 4y 4y FU
efficacy. involvement CD34+ arm at 4y FU FU
or progressive selected graft
diffuse skin
disease (<2y)
with no
visceral
involvement
SCOT (USA Phase II, open HSCT versus Global rank Any form of 55 (33 HSCT TBI 74% in HSCT 18% (6/33) in 6% (2/33) in 86% in HSCT
multicenter)/2018100 label, 12 monthly composite early SSc arm and 32 800 cGy + CY arm and 47% HSCT arm HSCT arm. arm and 51%
randomized CY pulses score at 54 (<5y) plus CY rm) 120 mg/kg + in CY arm, at and 41% Zero in the in CY arm, at
1:1 months of FU interstitial 90 mg/kg 72 months FU (14/34) in CY CY group 72 months FU
lung disease eATG arm, at 54
or previous CD34+ months FU
scleroderma selected graft
renal crisis
PFS: progression-free survival; OS: overall survival; N: number of enrolled subjects; USA: United States of America; y: years; SSc: systemic sclerosis; TBI: total body irradiation; IV CY: intravenous
cyclophosphamide; eATG: equine anti-thymoglobulin; rATG: rabbit anti-thymoglobulin; FU: follow-up; HSCT: hematopoietic stem cell transplantation; rATG*: this center used ATG-Fresenius (Neovii-
Biotech, Germany).
77
(EBMT) compared SSc patients transplanted with or with- an essential role in the pathogenesis of numerous autoim-
out graft selection, showing similar clinical outcomes.101 mune diseases. The perturbation of the TLR signaling pathway
Although not statistically significant, patients who received in intestinal macrophages has been associated with toler-
unselected grafts tended to have better overall and disease- ance breakdown in autoimmune diseases.114 Patients with
free survival than patients treated with selected grafts. More Crohn’s disease present defects in the innate immune path-
recently, a second prospective observational study from the way, and inadequate T cell responses to pathogenic mutations
EBMT reported, conversely, higher disease improvement rates in the nucleotide-binding oligomerization domain 2 (NOD2)
after HSCT with CD34+ graft selection, although there was no and autophagy-related protein 16-1 (ATG16L1) genes that
impact on the progression-free survival.102 A third, smaller, impair bacterial sensing and clearing.108 Imbalances between
recent study has also shown better outcomes in patients trans- natural (nTreg) and induced regulatory T-cells (iTreg), and
planted with selected versus non-selected grafts (Table 3).103 effector T-helper (Th) cells (Th1/Th17) that defend the mucosa
In summary, the question shall not be settled without a from bacteria, fungi and viruses are associated with Crohn’s
prospective randomized trial. disease.108,115 The Genoma Wide Association Study Project
Most transplant centers adopt non-myeloablative con- identified 71 susceptibility loci on 17 chromosomes and
ditioning regimens, however a group of North American regions related to inflammatory bowel disease, renamed IBD1
multicenter investigators, from 26 transplant sites, has consis- to IBD9.116
tently reported their experience with myeloablative protocols The age at diagnosis, disease location and behavior along
including full body irradiation.95,104 In this scenario, the most the gastrointestinal tract are defined according to Mon-
recently published randomized trial (SCOT trial) has shown treal classification.117 The cardinal symptoms of Crohn’s
good results in the myeloablative transplant group (Table 3).100 disease include abdominal pain, diarrhea, hematochezia,
The experience with allogeneic transplantation for sys- bloody stools, fatigue, weight loss, fever, recurrent fistulas,
temic sclerosis is limited to isolated case reports.14,105,106 and extraintestinal manifestations.118 Extraintestinal mani-
Therefore, clinical evidence is insufficient to recommend this festations are common, such as arthropathy (both axial and
treatment modality for patients with SSc. peripheral), ocular involvement (uveitis, scleritis, and episcle-
ritis), dermatological (including pyoderma gangrenosum and
Guidelines for transplantation in systemic sclerosis erythema nodosum), nephrolithiasis, hepatobiliary involve-
ment (primary sclerosing cholangitis), cholelithiasis, venous
The three randomized studies already published provide solid or arterial thromboembolism, and other associated immune-
evidence to recommend autologous hematopoietic stem cell mediated diseases.119
transplantation for severe and progressive cases of systemic The majority of patients (80%) present small bowel involve-
sclerosis. According to the Oxford Center for Evidence-Based ment, 1/3 only ileitis, 1/3 ileocolonic involvement and in 1/3,
Medicine’s evidence table,107 we consider the evidence to have Crohn’s disease is restricted to the colon and rectum. In
Grade A and Level 1B. Patients should be thoroughly evalu- a North American cohort, 30% of patients presented peri-
ated for heart dysfunction and fibrosis before transplantation anal disease, while in Europe this complication was detected
and the procedure should be performed in centers with expe- in only 9% of patients.120 Oral and gastroduodenal involve-
rience in managing patients with systemic sclerosis during ment is estimated in approximately 10% of Crohn’s disease
transplantation. patients.120 Fistulas are common: enteric, cutaneous, vesi-
cal, vaginal, anal, or rectal. Complications in the involved
organs, such as abdominal masses and abscesses, are fre-
Crohn’s disease quent, with perianal fistulizing disease in up to one-quarter
of the patients.119 At diagnosis, most (71%) patients present
Crohn’s disease is a chronic relapse-remitting inflammatory a non-stricturing and non-penetrating profile of disease, but
bowel disorder that can affect any site of the digestive tract.108 21% have a stricturing and 8% a penetrating behavior.120
Currently, Crohn’s is a global disease, with increasing world- Surgery due to intestinal inflammation or related complica-
wide incidence and prevalence.109 In Brazil, the prevalence of tions, such as stenosis, fistulas or perforations, occurs in 13%
Crohn’s disease varies according to the region of the coun- of patients in the first year of diagnosis, and 22% in five years
try, from 12.8/100,000 in the Northeastern area, to 14.1 and of follow-up. The 10-year cumulative risk of major abdominal
24.3/100,000 in the states of Espírito Santo and São Paulo, surgery is of approximately 55%.108,109,119,120
respectively.110–112 Diagnosis of Crohn’s disease is based on the com-
The disease is immunologically mediated and heteroge- bination of a history of chronic intestinal inflammation
neous among the affected patients. The imbalanced and symptoms and colonoscopy, magnetic resonance enterog-
dysregulated immunity of the intestinal mucosa provides raphy and histopathological findings.119 Routine laboratory
an inappropriate response against original intestinal flora or studies include complete blood count, basic metabolic panel,
luminal antigens. These responses are responsible for the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP),
symptoms and the intestinal lesions observed in Crohn’s liver function tests, iron distribution studies, vitamin B12 and
disease. Disturbances in the intestinal mucosa occur in D levels, ␤2 microglobulin and an immunologic panel study.121
patients genetically predisposed and exposed to environmen- Ileocolonoscopy and biopsy are considered gold standard
tal triggers.113 tools for diagnosis of Crohn’s disease. When visualizing the
The mucosal disturbance may be linked to abnormali- ileum, right, transverse and left colon, abnormalities in the
ties in the toll-like recognition receptors (TLRs), which play rectum mucosa and lesions are observed as cobblestones, with
Table 4 – Results of Crohn’s disease study outcomes.
rate
Single-arm studies
Italy (Milan) Phase I/II None, single Safety and CDAI > 250 4 CY 200 mg/kg + 75% at 16.5 25% (1/4) at Zero at 16.5 100% at 16.5
2007136 Prospective arm clini- Active 7.5 mg/kg rATG months 16.5 months months months
cal/endoscopic intestinal Unselected mean FU mean FU
response lesions graft
Failed > 2 IS
C-reactive
pro-
tein > 1 mg/dL
EUA (Chicago) Phase I/II None, single Safety and CDAI > 250 24 CY 19% at 5y 15/23 at mean Zero TRM 95% at 5y

20104 Prospective arm clinical Crohn’s 200 mg/kg + 6 mg/kg FU of 4.4y 1 accidental
outcomes severity rATG or death at 3y
index > 16 90 mg/kg eATG
Failed CD34+ selected
anti-TNF graft
Netherlands Case series None, single None Active 3 CY 200 mg/kg + Zero at 5y 100% (2/2) at Zero 100% at 5y
2011137 arm described disease (only 2 90 mg/kg eATG (both patients 5y
Failed transplanted) CD34+ selected relapsed at 3
anti-TNF graft and 12 m
Risk of post-AHSCT
resection
surgery
Germany Phase I/II None, single Safety, Active 12 (only 9 CY 200 mg/kg 17% (2/12) at 78% (7/9) at Zero at mean 100% at mean
(Freiburg) 2012138 Prospective arm feasibility disease transplanted) mean 3.1y 3.1y 3.1y
and efficacy Failed CD34+ selected follow-up of
conventional graft 3.1y
therapy
United Kingdom (3 Retrospective None, single Long-term Active 6 CY 200 mg/kg + Zero (6/6 100% at Zero 100% at
centers) 2014139 case series arm clinical disease failed 7.5 mg/kg rATG relapses) median 10 median 87
outcomes conventional CD34+ selected months after months FU
therapy graft in 2 AHSCT
patients
Brazil (S. José do Phase I/II None, single Safety and CDAI > 150 14 CY 200 mg/kg + 93% at 30 1/14 at 30 Zero at 30 100% at 30
Rio Preto) 2017142 Prospective arm early clinical Active 6.5 mg/kg rATG days days days days
outcomes intestinal Unselected
(first 30 days lesions graft
after AHSCT) Risk of
resection
surgery
Failed
anti-TNF
79
80
rate
Europe Retrospective None, single Safety and Patients 82 86% CY 54% at 1y 73% (60/81) at 1.2% (1/82) 97% at 5y
multicenter (EBMT) survey arm efficacy transplanted 200 mg/kg + 27% at 41 median 10
2018143 from 1997 to ATG months months after
2015 11% CY AHSCT
Excludes 200 mg/kg + CD34

ASTIC selection
patients
Spain (Madrid) Retrospective None, single Safety and Patients with 7 CY 29% at 48 71% (5/7) at Zero 100%
2019144 case series arm efficacy active 200 mg/kg + rATG months 48 months
Crohn’s (dose not
disease described)
transplanted Unselected
from 2011 to graft
2017.
Randomized study
ASTIC (EBMT, Phase II, open Patients Sustained Active 45 (23 AHSCT CY 200 mg/kg + 8.7% (2/23) in 95% (20/21) in 4.3% (1/23) at 96% at 1y in
multicenter) 2016140 label, randomized clinical and disease and 22 7.5 mg/kg rATG the AHSCT the AHSCT 1y in the the
randomized after endo- Impaired control Unselected group group at 1y transplant transplant
1:1 mobilization scopic/radiologic func- treatment) graft 94% (16/17) in group group
to immediate remission at tion/quality 4.5% (1/22) in the control Zero in the 100% in the
AHSCT or 1y of life the control group at 1y control group control group
control Failed ≥3 group
treatment IS/biologicals
with AHSCT
deferred for
1y
PFS: progression-free survival; OS: overall survival; N: number of enrolled subjects; USA: United States of America; y: years; CDAI: Crohn’s disease activity index; TRM: transplant-related mortality;
IV CY: intravenous cyclophosphamide; eATG: equine anti-thymoglobulin; rATG: rabbit anti-thymoglobulin; FU: follow-up; HSCT: hematopoietic stem cell transplantation; anti-TNF: treatment with
anti-tumor necrosis factor monoclonal antibody; IS: immunosuppressors; biologicals: biological agents.
nodularity, edema, superficial or deep ulcerations, friability, registry reports Crohn’s disease as the third most frequent
or stenosis. The Crohn’s Disease Endoscopy Severity Index autoimmune disease indication for AHSCT.141
(CDEIS) and the Simple Endoscopy Score for Crohn’s disease In Brazil, the first report of AHSCT for Crohn’s disease was
(SES-CD) were developed and validated to evaluate the com- published in 2013.142 To date, at least 57 procedures have
promised intestinal surface, and to characterize the severity of been performed in four Brazilian centers (unpublished data).
the involvement.122,123 All lesions should be biopsied for his- A single institution Brazilian trial enrolled 14 Crohn’s dis-
tological study. Upper endoscopy should only be performed ease patients for AHSCT with high rate of disease remissions
in patients with upper gastrointestinal signs and symptoms and improved quality of life at 30 days post-transplantation
and wireless capsule endoscopy may be an option for patients (Table 4).146 Longer follow-up of the quality of life in these
without intestinal strictures.119 Magnetic resonance enterog- patients, evaluated by the IBDQ (Inflammatory Bowel Dis-
raphy is a suitable method for the diagnosis, as the location, ease Questionnaire) and SF-36 (Short Form-36) questionnaires
extension, disease activity, presence of obstructions, fistulas, show sustained benefit at four years post-AHSCT (data not
and severity of inflammatory lesions of Crohn’s disease need published).
to be determined.124 The field of AHSCT for Crohn’s disease has advanced over
Disease activity is measured by scores, such as the Crohn’s time, in parallel to the learning curve in other autoimmune
Disease Activity Index (CDAI), and the Harvey Bradshaw index disease indications. Patient selection and disease stratifica-
(HBi).125,126 A CDAI below 150 is defined as disease remission. tion are important steps that precede AHSCT, and aim to
A HBi below five defines remission, 5–7 mildly active disease, improve safety and post-transplantation outcomes.46,143 Peri-
8–16 moderately active disease and higher than 16, severe dis- anal disease, fistulas and intra-abdominal abscesses, as well
ease. as presence of ostomies, are not considered absolute exclu-
Treatment aims to stabilize Crohn’s disease, reduce symp- sion criteria, but increase risks associated to the procedure
toms, and heal intestinal lesions. Anti-inflammatory drugs, and should be carefully considered before patient enrollment.
immunosuppressive agents, corticosteroids, and biological Moreover, hematopoietic progenitor cells may be success-
agents are prescribed alone or in combination. Drugs are usu- fully and safely mobilized from the peripheral blood with
ally administered in a stepwise sequence, named “up and low (2 g/m2 ) doses of cyclophosphamide.147 Disease reactiva-
down” treatment. In more severe cases, early indication of bio- tion over time is still high (Table 4) and whether CD34+ graft
logical agents associated with immunosuppressants remain selection has any effect on long-term control remains to be
controversial and debated.108 defined.4,136–140,142,143 Finally, there is evidence to suggest that
after AHSCT, patients become more responsive to conven-
Hematopoietic stem cell therapy tional therapy than before the procedure.140,141 These aspects
should be explored in future studies.
Hematopoietic stem cell transplantation (HSCT) has emerged The new ongoing protocols, ASTIC-Lite (ASTIC-low inten-
as a potential treatment for Crohn’s disease due to the chronic- sity therapy evaluation, EBMT), and the AutoCrohn2 (São José
ity of the disease and lack of further therapeutic options in do Rio Preto, Brazil), include a more refined patient assessment
refractory patients. Additionally, since 1993, there are several and stratification with accurate clinical, immunological, mag-
case reports in the literature of Crohn’s disease patients with netic resonance and microbiota studies. These studies aim for
concomitant leukemia or lymphoma who improved from the a better understanding of the therapeutic potential of AHSCT
former when transplanted for the latter.127–132 for patients with Crohn’s disease.147–149
In 2003, investigators from the Northwestern University
(Chicago, USA) published their successful experience with the Guidelines for transplantation in Crohn’s disease
first two patients treated with AHSCT for Crohn’s disease as
primary indication.133,134 A subsequent update from the same Autologous HSCT has the potential to induce clinical remis-
investigators described dramatic clinical remissions in 11 from sion and improve quality of life in patients with Crohn’s
a total of 12 transplanted patients, in 18 months of follow- disease with poor prognosis or that are refractory to immuno-
up.135 In 2010, a last update described the long-term follow-up suppressants or biologic agents. AHSCT is considered safe,
of 24 Crohn’s disease patients transplanted in Chicago, show- but associated with a high number of adverse events, mainly
ing high rates of disease progression over a five-year follow-up infectious. Therefore, AHSCT for Crohn’s disease should be
(Table 4).4 performed by experienced centers, with specialized teams to
The European centers also reproduced the North-American manage gastrointestinal and infectious complications. Early
protocol, with similar outcomes of low toxicity and high rates referral is recommended to optimize clinical outcomes and
of short-term disease remission.136 Longer follow-up, how- minimize risks.
ever, confirmed the high relapse/progression rates.137–144 A
European multicenter randomized study (Autologous Stem
Cell Transplantation in Refractory Crohn’s Disease, ASTIC) had Conclusions
a very strict study design and ambitious endpoints, and thus
failed to show superiority of AHSCT versus mobilization only Scientific evidence supports the clinical use of autologous
(Table 4).140 A later reassessment of the same results, with hematopoietic stem cell transplantation (AHSCT) for multi-
more traditional endpoints, enabled more optimistic conclu- ple sclerosis (MS), systemic sclerosis and Crohn’s disease. In
sions; that AHSCT promotes clinical and endoscopic benefits, systemic sclerosis, AHSCT is indicated due to the severity of
despite a high burden of adverse events.145 To date, the EBMT the disease and lack of therapeutic options, with effectiveness
confirmed by phase III randomized trials. In MS, treatment diseases: updated guidelines of the European Group for
with AHSCT is supported by 25 years of research, including Blood and Marrow Transplantation. Bone Marrow
recent phase III trials comparing transplant to new drugs. In Transplant. 2012;47(6):770–90.
Crohn’s disease refractory to treatment with immunosuppres- 11. Del Papa N, Onida F, Zaccara E, Saporiti G, Maglione W,
Tagliaferri E, et al. Autologous hematopoietic stem cell
sor and biological agents, long-term benefits have been shown
transplantation has better outcomes than conventional
after AHSCT, despite low rates of sustained disease remission. therapies in patients with rapidly progressive systemic
The role of HSCT in these and in other autoimmune sclerosis. Bone Marrow Transplant. 2017;52(1):53–8.
diseases is likely to evolve further with increased clinical expe- 12. Henes JC, Schmalzing M, Vogel W, Riemekasten G, Fend F,
rience, especially with regards to optimal timing of transplant. Kanz L, et al. Optimization of autologous stem cell
It is expected that improvements in design of clinical trials transplantation for systemic sclerosis – a single-center
longterm experience in 26 patients with severe organ
and experimental studies further expand the impact of HSCT
manifestations. J Rheumatol. 2012;39(2):269–75.
in this field.
13. De Santis GC, de Pina Almeida Prado B, de Lima Prata K,
Brunetta DM, Orellana MD, Palma PVB, et al. Mobilization
Conflicts of interest and harvesting of PBPC in newly diagnosed type 1 diabetes
mellitus. Bone Marrow Transplant. 2012;47(7):993–4.
14. Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E,
The authors declare no conflicts of interest.
Marjanovic Z, et al. Evolution, trends, outcomes, and
economics of hematopoietic stem cell transplantation in
Funding severe autoimmune diseases. Blood Adv. 2017;1(27):2742–55.
15. Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A,
Kohler S, et al. Depletion of autoreactive immunologic
This research did not receive any specific grant from funding memory followed by autologous hematopoietic stem cell
agencies in the public, commercial, or not-for-profit sectors. transplantation in patients with refractory SLE induces
long-term remission through de novo generation of a
references juvenile and tolerant immune system. Blood.
2009;113(1):214–23.
16. Weiner HL. Multiple sclerosis is an inflammatory
T-cell-mediated autoimmune disease. Arch Neurol.
1. Snowden JA, Badoglio M, Alexander T. The rise of autologous 2004;61(10):1613.
HCT for autoimmune diseases: what is behind it and what 17. Compston A, Coles A. Multiple sclerosis. Lancet.
does it mean for the future of treatment? An update on 2008;372(9648):1502–17.
behalf of the EBMT Autoimmune Diseases Working Party. 18. Goodin DS. The epidemiology of multiple sclerosis. In:
Expert Rev Clin Immunol. 2018;15(10):981–5. Handbook of clinical neurology [Internet]; 2014. p. 231–66.
2. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla 19. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest.
KR, Park M, et al. High-dose immunosuppressive therapy 2012;122(4):1180–8.
and autologous peripheral blood stem cell transplantation 20. Roach ES. Is multiple sclerosis an autoimmune disorder?
for severe multiple sclerosis. Blood. 2003;102(7):2364–72. Arch Neurol. 2004;61(10):1615.
3. Kozák T, Havrdová E, Pit’ha J, Gregora E, Pytlík R, Maaloufová 21. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N
J, et al. High-dose immunosuppressive therapy with PBPC Engl J Med. 2018;378(2):169–80.
support in the treatment of poor risk multiple sclerosis. 22. Ramagopalan SV, Sadovnick AD. Epidemiology of multiple
Bone Marrow Transplant. 2000;25(5):525–31. sclerosis. Neurol Clin. 2011;29(2):207–17.
4. Burt RK, Craig RM, Milanetti F, Quigley K, Gozdziak P, Bucha J, 23. Atlas multiple sclerosis resources in the world [Internet];
et al. Autologous nonmyeloablative hematopoietic stem cell 2008. Available from: https://www.who.int/mental health
transplantation in patients with severe anti-TNF refractory /neurology/Atlas MS WEB.pdf [cited 16.11.19].
Crohn disease: long-term follow-up. Blood. 24. MS movement problems | multiple sclerosis. Multiple
2010;116(26):6123–32. Sclerosis International Federation; 2016.
5. Hawkey CJ, Lindsay J, Gribben J. Stem cell transplantation for 25. Kurtzke JF. Clinical definition for multiple sclerosis
refractory Crohn disease – reply. JAMA. 2016;315(23):2620. treatment trials. Ann Neurol. 1994;36(S1):S73–9.
6. Mancardi G, Saccardi R. Autologous haematopoietic 26. Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer
stem-cell transplantation in multiple sclerosis. Lancet K, Marta M. Is it time to target no evident disease activity
Neurol. 2008;7(7):626–36. (NEDA) in multiple sclerosis? Mult Scler Relat Disord.
7. Su L, Xu J, Ji B-X, Wan S-G, Lu C-Y, Dong H-Q, et al. 2015;4(4):329–33.
Autologous peripheral blood stem cell transplantation for 27. Garry T, Krieger S, Fabian M. MS research update [Internet];
severe multiple sclerosis. Int J Hematol. 2006;84(3):276–81. 2018. Available from:
8. Openshaw H, Lund BT, Kashyap A, Atkinson R, Sniecinski I, https://mymsaa.org/PDFs/MSAA Research Update 2018.pdf
Weiner LP, et al. Peripheral blood stem cell transplantation [cited 16.11.19].
in multiple sclerosis with busulfan and cyclophosphamide 28. Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y,
conditioning: report of toxicity and immunological et al. Hematopoietic stem cell transplantation for
monitoring. Biol Blood Marrow Transplant. 2000;6(5):563–75. progressive multiple sclerosis: failure of a total body
9. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van irradiation-based conditioning regimen to prevent disease
Laar J, et al. Autologous hematopoietic stem cell progression in patients with high disability scores. Blood.
transplantation for autoimmune diseases: an observational 2003;102(7):2373–8.
study on 12 years’ experience from the European Group for 29. Carreras E, Saiz A, Marín P, Martínez C, Rovira M, Villamor
Blood and Marrow Transplantation Working Party on N, et al. CD34+ selected autologous peripheral blood stem
Autoimmune Diseases. Haematologica. 2010;95(2):284–92. cell transplantation for multiple sclerosis: report of toxicity
10. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, and treatment results at one year of follow-up in 15
Cervera R, et al. Haematopoietic SCT in severe autoimmune patients. Haematologica. 2003;88(3):306–14.
30. Samijn JPA, te Boekhorst PAW, Mondria T, van Doorn PA, 46. Tyndall A, Fassas A, Passweg J, Ruiz de Elvira C, Attal M,
Flach HZ, van der Meché FGA, et al. Intense T cell depletion Brooks P, et al. Autologous haematopoietic stem cell
followed by autologous bone marrow transplantation for transplants for autoimmune disease–feasibility and
severe multiple sclerosis. J Neurol Neurosurg Psychiatry. transplant-related mortality. Autoimmune Disease and
2006;77(1):46–50. Lymphoma Working Parties of the European Group for Blood
31. Atkins H, Freedman M. Immune ablation followed by and Marrow Transplantation, the European League Against
autologous hematopoietic stem cell transplantation for the Rheumatism and the International Stem Cell Project for
treatment of poor prognosis multiple sclerosis. Methods Mol Autoimmune Disease. Bone Marrow Transplant.
Biology. 2009:231–46. 1999;24(7):729–34.
32. Fassas A, Kimiskidis VK, Sakellari I, Kapinas K, 47. Mancardi GL, Murialdo A, Rossi P, Gualandi F, Martino G,
Anagnostopoulos A, Tsimourtou V, et al. Long-term results Marmont A, et al. Autologous stem cell transplantation as
of stem cell transplantation for MS: a single-center rescue therapy in malignant forms of multiple sclerosis.
experience. Neurology. 2011;76(12):1066–70. Mult Scler J. 2005;11(3):367–71.
33. Saiz A, Blanco Y, Berenguer J, Gómez-Choco M, Carreras E, 48. Fagius J, Lundgren J, Oberg G. Early highly aggressive MS
Arbizu T, et al. Clinical outcome 6 years after autologous successfully treated by hematopoietic stem cell
hematopoietic stem cell transplantation in multiple transplantation. Mult Scler.
sclerosis. Neurologia. 2008;23(7):405–7. 2009;15(2):229–37.
34. Kozák T, Havrdová E, Pit’ha J, Gregora E, Pytlík R, Maaloufová 49. Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F,
J, et al. Immunoablative therapy with autologous stem cell Amato MP, et al. Autologous haematopoietic stem cell
transplantation in the treatment of poor risk multiple transplantation with an intermediate intensity conditioning
sclerosis. Transplant Proc. 2001;33(3):2179–81. regimen in multiple sclerosis: the Italian multi-centre
35. Shevchenko YL, Novik AA, Kuznetsov AN, Afanasiev BV, experience. Mult Scler. 2012;18(6): 835–42.
Lisukov IA, Kozlov VA, et al. High-dose immunosuppressive 50. Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C,
therapy with autologous hematopoietic stem cell Carpenter PA, et al. Autologous hematopoietic cell
transplantation as a treatment option in multiple sclerosis. transplantation for treatment-refractory relapsing multiple
Exp Hematol. 2008;36(8):922–8. sclerosis: position statement from the American Society for
36. Xu J, Ji B, Su L, Dong H, Sun X, Liu C. Clinical outcomes after Blood and Marrow Transplantation. Biol Blood Marrow
autologous haematopoietic stem cell transplantation in Transplant. 2019;25(5):845–54.
patients with progressive multiple sclerosis. Chin Med J 51. Mancardi GL. ASTIMS: High dose immunoablation and
(Engl). 2006;119(22):1851–5. autologous haematopoietic stem cell transplantation versus
37. Ni X-S, Ouyang J, Zhu W-H, Wang C, Chen B. Autologous mitoxantrone therapy in severe multiple sclerosis | EBMT
hematopoietic stem cell transplantation for progressive [Internet]. Available from: https://www.ebmt.org/research/
multiple sclerosis: report of efficacy and safety at three yr of studies/astims-high-dose-immunoablation-and-autologous
follow up in 21 patients. Clin Transplant. 2006;20(4):485–9. -haematopoietic-stem-cell [cited 16.11.19].
38. Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di 52. Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E,
Bartolomeo P, et al. Autologous HSCT for severe progressive Merelli E, et al. Autologous hematopoietic stem cell
multiple sclerosis in a multicenter trial: impact on disease transplantation in multiple sclerosis: a phase II trial.
activity and quality of life. Blood. 2005;105(6):2601–7. Neurology. 2015;84(10):981–8.
39. Krasulová E, Trneny M, Kozák T, Vacková B, Pohlreich D, 53. Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas
Kemlink D, et al. High-dose immunoablation with A, et al. Long-term outcomes after autologous
autologous haematopoietic stem cell transplantation in hematopoietic stem cell transplantation for multiple
aggressive multiple sclerosis: a single centre 10-year sclerosis. JAMA Neurol. 2017;74(4):459.
experience. Mult Scler. 2010;16(6):685–93. 54. Sormani MP, Muraro PA, Schiavetti I, Signori A, Laroni A,
40. Breban M, Hammer RE, Richardson JA, Taurog JD. Transfer of Saccardi R, et al. Autologous hematopoietic stem cell
the inflammatory disease of HLA-B27 transgenic rats by transplantation in multiple sclerosis: a meta-analysis.
bone marrow engraftment. J Exp Med. 1993;178(5):1607–16. Neurology. 2017;88(22):2115–22.
41. de Kleer I, Vastert B, Klein M, Teklenburg G, Arkesteijn G, 55. Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA,
Yung GP, et al. Autologous stem cell transplantation for Oliveira MC, et al. Effect of nonmyeloablative hematopoietic
autoimmunity induces immunologic self-tolerance by stem cell transplantation vs continued disease-modifying
reprogramming autoreactive T cells and restoring the therapy on disease progression in patients with
CD4+CD25+ immune regulatory network. Blood. relapsing-remitting multiple sclerosis. JAMA.
2006;107(4):1696–702. 2019;321(2):165.
42. Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H, Thomson 56. Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson
AW. Retroviral delivery of viral interleukin-10 into myeloid M, Nilsson P, et al. Autologous haematopoietic stem cell
dendritic cells markedly inhibits their allostimulatory transplantation for aggressive multiple sclerosis: the
activity and promotes the induction of T-cell Swedish experience. J Neurol Neurosurg Psychiatry.
hyporesponsiveness. Transplantation. 1998;66(12):1567–74. 2014;85(10):1116–21.
43. Herrmann MM, Gaertner S, Stadelmann C, van den Brandt J, 57. Casanova B, Jarque I, Gascón F, Hernández-Boluda JC,
Böscke R, Budach W, et al. Tolerance induction by bone Pérez-Miralles F, de la Rubia J, et al. Autologous
marrow transplantation in a multiple sclerosis model. hematopoietic stem cell transplantation in
Blood. 2005;106(5):1875–83. relapsing-remitting multiple sclerosis: comparison with
44. Burt RK, Cohen B, Rose J, Petersen F, Oyama Y, Stefoski D, secondary progressive multiple sclerosis. Neurol Sci.
et al. Hematopoietic stem cell transplantation for multiple 2017;38(7):1213–21.
sclerosis. Arch Neurol. 2005;62(6):860–4. 58. Shevchenko JL, Kuznetsov AN, Ionova TI, Melnichenko VY,
45. Good RA, Verjee T. Historical and current perspectives on Fedorenko DA, Kartashov AV, et al. Autologous
bone marrow transplantation for prevention and treatment hematopoietic stem cell transplantation with
of immunodeficiencies and autoimmunities. Biol Blood reduced-intensity conditioning in multiple sclerosis. Exp
Marrow Transplant. 2001;7(3):123–35. Hematol. 2012;40(11):892–8.
59. Burt RK, Loh Y, Cohen B, Stefoski D, Stefosky D, Balabanov R, 74. Domsic RT, Nihtyanova SI, Wisniewski SR, Fine MJ, Lucas M,
et al. Autologous non-myeloablative haemopoietic stem cell Kwoh CK, et al. Derivation and validation of a prediction
transplantation in relapsing-remitting multiple sclerosis: a rule for two-year mortality in early diffuse cutaneous
phase I/II study. Lancet Neurol. 2009;8(3): systemic sclerosis. Arthritis Rheumatol. 2014;66(6):1616–24.
244–53. 75. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in
60. Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith mortality in patients with systemic sclerosis over 40 years: a
LM, et al. High-dose immunosuppressive therapy and systematic review and meta-analysis of cohort studies.
autologous hematopoietic cell transplantation for Rheumatology (Oxford). 2012;51(6):1017–26.
relapsing-remitting multiple sclerosis (HALT-MS). JAMA 76. LeRoy EC, Medsger TA. Criteria for the classification of early
Neurol. 2015;72(2):159. systemic sclerosis. J Rheumatol. 2001;28(7):1573–6.
61. Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, 77. Wollheim FA. Classification of systemic sclerosis. Visions
Steinmiller KC, et al. High-dose immunosuppressive therapy and reality. Rheumatology. 2005;44(10):1212–6.
and autologous HCT for relapsing-remitting MS. Neurology. 78. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A,
2017;88(9):842–52. Allanore Y, et al. Update of EULAR recommendations for the
62. Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or treatment of systemic sclerosis. Ann Rheum Dis.
A, et al. Immunoablation and autologous haemopoietic 2017;76(8):1327–39.
stem-cell transplantation for aggressive multiple sclerosis: a 79. Sampaio-Barros PD, Zimmermann AF, Müller CdS, Borges
multicentre single-group phase 2 trial. Lancet. CTL, Freire EAM, Maretti GB. Recommendations for the
2016;388(10044):576–85. management and treatment of systemic sclerosis. Rev Bras
63. Moore JJ, Massey JC, Ford CD, Khoo ML, Zaunders JJ, Reumatol. 2013;53(3):258–75.
Hendrawan K, et al. Prospective phase II clinical trial of 80. Lopez-Ovejero JA, Saal SD, D’Angelo WA, Cheigh JS, Stenzel
autologous haematopoietic stem cell transplant for KH, Laragh JH. Reversal of vascular and renal crises of
treatment refractory multiple sclerosis. J Neurol Neurosurg scleroderma by oral angiotensin-converting-enzyme
Psychiatry. 2019;90(5):514–21. blockade. N Engl J Med. 1979;300(25):1417–9.
64. Sormani MP, Muraro PA, Saccardi R, Mancardi G. NEDA 81. Steen VD, Costantino JP, Shapiro AP, Medsger TA. Outcome
status in highly active MS can be more easily obtained with of renal crisis in systemic sclerosis: relation to availability of
autologous hematopoietic stem cell transplantation than angiotensin converting enzyme (ACE) inhibitors. Ann Intern
other drugs. Mult Scler. 2017;23(2):201–4. Med. 1990;11(5):352–7.
65. Hamerschlak N, Rodrigues M, Moraes DA, Oliveira MC, 82. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE,
Stracieri ABPL, Pieroni F, et al. Brazilian experience with two Silver RM, et al. Effects of 1-year treatment with
conditioning regimens in patients with multiple sclerosis: cyclophosphamide on outcomes at 2 years in scleroderma
BEAM/horse ATG and CY/rabbit ATG. Bone Marrow lung disease. Am J Respir Crit Care Med.
Transplant. 2010;45(2):239–48. 2007;176(10):1026–34.
66. Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, 83. Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D,
Havrdova E, et al. Autologous stem cell transplantation for Hoffmann-Vold A-M, et al. Mycophenolate mofetil versus
progressive multiple sclerosis: update of the European placebo for systemic sclerosis-related interstitial lung
Group for Blood and Marrow Transplantation autoimmune disease: an analysis of scleroderma lung studies I and II.
diseases working party database. Mult Scler. Arthritis Rheumatol. 2017;69(7):1451–60.
2006;12(6):814–23. 84. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM,
67. Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong Anderson ME, et al. Safety and efficacy of subcutaneous
X, Ahn KW, et al. Transplantation for autoimmune diseases tocilizumab in adults with systemic sclerosis (faSScinate): a
in north and South America: a report of the Center for phase 2, randomised, controlled trial. Lancet.
International Blood and Marrow Transplant Research. Biol 2016;387(10038):2630–40.
Blood Marrow Transplant. 2012;18(10):1471–8. 85. Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM,
68. Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley Anderson ME, et al. Safety and efficacy of subcutaneous
K, et al. Association of nonmyeloablative hematopoietic tocilizumab in systemic sclerosis: results from the
stem cell transplantation with neurological disability in open-label period of a phase II randomised controlled trial
patients with relapsing-remitting multiple sclerosis. JAMA. (faSScinate). Ann Rheum Dis. 2018;77(2):212–20.
2015;313(3):275–84. 86. Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black
69. Rodrigues MC, de O, Hamerschlak N, de Moraes DA, Simões CM, et al. Relationship between change in skin score and
BP, Rodrigues M, et al. Guidelines of the Brazilian society of disease outcome in diffuse cutaneous systemic sclerosis:
bone Marrow transplantation on hematopoietic stem cell application of a latent linear trajectory model. Arthritis
transplantation as a treatment for the autoimmune diseases Rheum. 2007;56(7):2422–31.
systemic sclerosis and multiple sclerosis. Rev Bras Hematol 87. Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M,
Hemoter. 2013;35(2):134–43. Alegre Sancho JJ, et al. Outcomes of patients with systemic
70. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield sclerosis treated with rituximab in contemporary practice: a
DM, Miranda JL, et al. Metabolic syndrome and prospective cohort study. Ann Rheum Dis. 2019;78(7):979–87.
cardiovascular disease after hematopoietic cell 88. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z,
transplantation: screening and preventive practice Larghero J, et al. Autologous hematopoietic stem cell
recommendations from the CIBMTR and EBMT. Biol Blood transplantation vs intravenous pulse cyclophosphamide in
Marrow Transplant. 2016;22(8):1493–503. diffuse cutaneous systemic sclerosis: a randomized clinical
71. Denton CP, Wells AU, Coghlan JG. Major lung complications trial. JAMA. 2014;311(24):2490–8.
of systemic sclerosis. Nat Rev Rheumatol. 2018;14(9): 89. Burt RK, Oliveira MC, Shah SJ, Moraes DA, Simoes B,
511–27. Gheorghiade M, et al. Cardiac involvement and
72. Denton CP, Khanna D. Systemic sclerosis. Lancet. treatment-related mortality after non-myeloablative
2017;390(10103):1685–99. haemopoietic stem-cell transplantation with unselected
73. Varga J, Abraham D. Systemic sclerosis: a prototypic autologous peripheral blood for patients with systemic
multisystem fibrotic disorder. J Clin Invest. sclerosis: a retrospective analysis. Lancet.
2007;117(3):557–67. 2013;381(9872):1116–24.
90. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron autologous haematopoietic stem cell transplantation in the
M, Tyndall A, et al. Classification criteria for systemic treatment of severe systemic sclerosis: a post hoc analysis
sclerosis: an American College of Rheumatology/European of a phase I/II clinical trial conducted in Japan. Arthritis Res
League Against Rheumatism Collaborative Initiative. Ther. 2019;21(1):30.
Arthritis Rheum. 2013;65(11):2737–47. 104. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ,
91. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Dansey R, et al. High-dose immunosuppressive therapy for
Besenthal C, et al. Phase I/II trial of autologous stem cell severe systemic sclerosis: initial outcomes. Blood.
transplantation in systemic sclerosis: procedure related 2002;100(5):1602–10.
mortality and impact on skin disease. Ann Rheum Dis. 105. Loh Y, Oyama Y, Statkute L, Verda L, Quigley K, Yaung K,
2001;60(6):577–84. et al. Non-myeloablative allogeneic hematopoietic stem cell
92. Burt RK, Oyama Y, Traynor A, Quigley K, Brush M, Rodriguez transplantation for severe systemic sclerosis:
J, et al. Hematopoietic stem cell transplantation for systemic graft-versus-autoimmunity without graft-versus-host
sclerosis with rapid improvement in skin scores: is disease? Bone Marrow Transplant. 2007;39(7):435–7.
neoangiogenesis occurring? Bone Marrow Transplant. 106. Shiratsuchi M, Motomura S, Abe Y, Shiokawa S, Nishimura J.
2003;32(S1):S65–7. Long-term follow-up after nonmyeloablative allogeneic
93. Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, hematopoietic stem cell transplantation for systemic
Mounier N, et al. Autologous bone marrow transplantation sclerosis. Clin Rheumatol. 2008;27(9):1207–9.
in the treatment of refractory systemic sclerosis: early 107. Oxford Centre for Evidence-based Medicine – Levels of
results from a French multicentre phase I–II study. Br J Evidence (March 2009) – CEBM [Internet]; 2009. Available
Haematol. 2002;119(3):726–39. from: https://www.cebm.net/2009/06/oxford-centre
94. Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, -evidence-based-medicine-levels
Finke J, et al. Autologous stem cell transplantation in the -evidence-march-2009/ [cited 16.11.19].
treatment of systemic sclerosis: report from the 108. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet.
EBMT/EULAR Registry. Ann Rheum Dis. 2004;63(8):974–81. 2012;380(9853):1590–605.
95. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen C-S, 109. Baumgart D. The natural history of inflammatory bowel
Godwin JD, et al. High-dose immunosuppressive therapy disease. In: Crohn’s disease and ulcerative colitis. New York:
and autologous hematopoietic cell transplantation for Springer; 2012.
severe systemic sclerosis: long-term follow-up of the US 110. Parente JML, Coy CSR, Campelo V, Parente MPPD, Costa LA,
multicenter pilot study. Blood. 2007;110(4):1388–96. da Silva RM, et al. Inflammatory bowel disease in an
96. Oyama Y, Barr WG, Statkute L, Corbridge T, Gonda EA, underdeveloped region of Northeastern Brazil. World J
Jovanovic B, et al. Autologous non-myeloablative Gastroenterol. 2015;21(4):1197–206.
hematopoietic stem cell transplantation in patients with 111. Lima Martins A, Volpato RA, Zago-Gomes MdP. The
systemic sclerosis. Bone Marrow Transplant. prevalence and phenotype in Brazilian patients with
2007;40(6):549–55. inflammatory bowel disease. BMC Gastroenterol.
97. Burt RK, Oliveira MC, Shah SJ. Cardiac assessment before 2018;18(1):87.
stem cell transplantation for systemic sclerosis. JAMA. 112. Gasparini RG, Sassaki LY, Saad-Hossne R. Inflammatory
2014;312(17):1803. bowel disease epidemiology in São Paulo State, Brazil. Clin
98. Farge D, Burt RK, Oliveira M-C, Mousseaux E, Rovira M, Exp Gastroenterol. 2018;11:423–9.
Marjanovic Z, et al. Cardiopulmonary assessment of 113. Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology,
patients with systemic sclerosis for hematopoietic stem cell diagnosis, and management. Mayo Clin Proc.
transplantation: recommendations from the European 2017;92(7):1088–103.
Society for Blood and Marrow Transplantation Autoimmune 114. Zhou Z, Ding M, Huang L, Gilkeson G, Lang R, Jiang W.
Diseases Working Party and collaborating partners. Bone Toll-like receptor-mediated immune responses in intestinal
Marrow Transplant. 2017;52(11):1495–503. macrophages; implications for mucosal immunity and
99. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, autoimmune diseases. Clin Immunol.
et al. Autologous non-myeloablative haemopoietic stem-cell 2016;173: 81–6.
transplantation compared with pulse cyclophosphamide 115. Pockley AG, Lindsay JO, Foulds GA, Rutella S, Gribben JG,
once per month for systemic sclerosis (ASSIST): an Alexander T, et al. Immune reconstitution after autologous
open-label, randomised phase 2 trial. Lancet. hematopoietic stem cell transplantation in Crohn’s disease:
2011;378(9790):498–506. current status and future directions. A review on behalf of
100. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, the EBMT Autoimmune Diseases Working Party and the
Pinckney A, Welch B, et al. Myeloablative autologous autologous stem cell transplantation in refra. Front
stem-cell transplantation for severe scleroderma. N Engl J Immunol. 2018;9:646.
Med. 2018;378(1):35–47. 116. Verstockt B, Smith KG, Lee JC. Genome-wide association
101. Oliveira MC, Labopin M, Henes J, Moore J, Papa ND, Cras A, studies in Crohn’s disease: past, present and future. Clin
et al. Does ex vivo CD34+ positive selection influence Transl Immunol. 2018;7(1):e1001.
outcome after autologous hematopoietic stem cell 117. Silverberg MS, Satsangi J, Ahmad T, Arnott IDR, Bernstein
transplantation in systemic sclerosis patients? Bone Marrow CN, Brant SR, et al. Toward an integrated clinical, molecular
Transplant. 2016;51(4):501–5. and serological classification of inflammatory bowel
102. Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del disease: report of a Working Party of the 2005 Montreal
Papa N, et al. Autologous stem cell transplantation for World Congress of Gastroenterology. Can J Gastroenterol.
progressive systemic sclerosis: a prospective 2005;19 Suppl A:5A–36A.
non-interventional study from the European Society for 118. Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice
Blood and Marrow Transplantation Autoimmune Disease Parameters Committee of American College of
Working Party. Haematologica. 2020;(January), Gastroenterology. Management of Crohn’s disease in adults.
http://dx.doi.org/10.3324/haematol.2019.230128. Am J Gastroenterol. 2009;104(2):465–83.
103. Ayano M, Tsukamoto H, Mitoma H, Kimoto Y, Akahoshi M, 119. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson
Arinobu Y, et al. CD34-selected versus unmanipulated LB, Sands BE. ACG Clinical Guideline: management of
Crohn’s disease in adults. Am J Gastroenterol. hematopoietic stem cell transplantation for severe
2018;113(4):481–517. refractory Crohn’s disease. J Crohn’s Colitis. 2011;5(6):543–9.
120. Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen 138. Hasselblatt P, Drognitz K, Potthoff K, Bertz H, Kruis W,
KW, Andersen V, et al. Natural disease course of Crohn’s Schmidt C, et al. Remission of refractory Crohn’s disease by
disease during the first 5 years after diagnosis in a European high-dose cyclophosphamide and autologous peripheral
population-based inception cohort: an Epi-IBD study. Gut. blood stem cell transplantation. Aliment Pharmacol Ther.
2019;68(3):423–33. 2012;36(8):725–35.
121. Gajendran M, Loganathan P, Catinella AP, Hashash JG. A 139. Snowden JA, Ansari A, Sachchithanantham S, Jackson G,
comprehensive review and update on Crohn’s disease. Thompson N, Lobo A, et al. Autologous stem cell
Disease-a-Month. 2018;64(2):20–57. transplantation in severe treatment-resistant Crohn’s
122. Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, disease: long-term follow-up of UK patients treated on
Maunoury V, et al. Development and validation of a new, compassionate basis. QJM. 2014;107(11):871–7.
simplified endoscopic activity score for Crohn’s disease: the 140. Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart
SES-CD. Gastrointest Endosc. 2004;60(4):505–12. E, et al. Autologous hematopoetic stem cell transplantation
123. Khanna R, Nelson SA, Feagan BG, D’Haens G, Sandborn WJ, for refractory Crohn disease a randomized clinical trial.
Zou G, et al. Endoscopic scoring indices for evaluation of JAMA. 2015;314(23):2524–34.
disease activity in Crohn’s disease. Cochrane Database Syst 141. Snowden JA, Panés J, Alexander T, Allez M, Ardizzone S,
Rev. 2016;(8):CD010642. Dierickx D, et al. Autologous haematopoietic stem cell
124. Lunder AK, Bakstad LT, Jahnsen J, Borthne A, Hov JR, Vatn M, transplantation (AHSCT) in severe Crohn’s disease: a review
et al. Assessment of bowel inflammation and strictures by on behalf of ECCO and EBMT. J Crohns Colitis.
magnetic resonance enterography in long-term Crohn’s 2018;12(4):476–88.
disease. J Crohns Colitis. 2019;13(5):607–14. 142. Ruiz MA, Kaiser Junior RL, Gouvêa Faria MA, de Quadros LG.
125. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Remission of refractory Crohn’s disease after autologous
Crohn’s disease activity index. National Cooperative Crohn’s hematopoietic stem cell transplantation. Rev Bras Hematol
Disease Study. Gastroenterology. 1976;70(3):439–44. Hemoter. 2015;37(2):136–9.
126. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease 143. Brierley CK, Castilla-Llorente C, Labopin M, Badoglio M,
activity. Lancet. 1980;1(8167):514. Rovira M, Ricart E, et al. Autologous haematopoietic stem
127. Drakos PE, Nagler A, Or R. Case of Crohn’s disease in bone cell transplantation for Crohn’s disease: a retrospective
marrow transplantation. Am J Hematol. 1993;43(2):157–8. survey of long-term outcomes from the European Society for
128. Kashyap A, Forman SJ. Autologous bone marrow Blood and Marrow Transplantation. J Crohns Colitis.
transplantation for non-Hodgkin’s lymphoma resulting in 2018;12(9):1097–103.
long-term remission of coincidental Crohn’s disease. Br J 144. Hernanz N, Sierra M, Volpato N, Núñez-Gómez L, Mesonero
Haematol. 1998;103(3):651–2. F, Herrera-Puente P, et al. Autologous haematopoietic stem
129. Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of cell transplantation in refractory Crohn’s disease: experience
Crohn’s disease after allogeneic marrow transplantation. in our centre. Gastroenterol Hepatol. 2019;42(1):16–22.
Gastroenterology. 1998;114(3):433–40. 145. Lindsay JO, Allez M, Clark M, Labopin M, Ricart E, Rogler G,
130. Musso M, Porretto F, Crescimanno A, Bondì F, Polizzi V, et al. Autologous stem-cell transplantation in
Scalone R. Crohn’s disease complicated by relapsed treatment-refractory Crohn’s disease: an analysis of pooled
extranodal Hodgkin’s lymphoma: prolonged complete data from the ASTIC trial. Lancet Gastroenterol Hepatol.
remission after unmanipulated PBPC autotransplant. Bone 2017;2(6):399–406.
Marrow Transplant. 2000;26(8):921–3. 146. Ruiz MA, Kaiser RL, de Quadros LG, Piron-Ruiz L,
131. Söderholm JD, Malm C, Juliusson G, Sjödahl R. Long-term Peña-Arciniegas T, Faria MAG, et al. Low toxicity and
endoscopic remission of crohn disease after autologous favorable clinical and quality of life impact after
stem cell transplantation for acute myeloid leukaemia. non-myeloablative autologous hematopoietic stem cell
Scand J Gastroenterol. 2002;37(5):613–6. transplant in Crohn’s disease. BMC Res Notes. 2017;10(1):495.
132. Ditschkowski M, Einsele H, Schwerdtfeger R, Bunjes D, 147. Ruiz MA, Kaiser RL, Ruiz LP, Peña-Arciniegas T, Castiglioni L,
Trenschel R, Beelen DW, et al. Improvement of inflammatory Saran PS, et al. Crohn’s disease patients effectively mobilize
bowel disease after allogeneic stem-cell transplantation. peripheral blood stem cells to perform autologous
Transplantation. 2003;75(10):1745–7. haematopoietic stem cell transplantation. bioRxiv.
133. Craig RM, Traynor A, Oyama Y, Burt RK. Hematopoietic stem 2018:348763.
cell transplantation for severe Crohn’s disease. Bone Marrow 148. Pereira N, Torres M, Moraes M, Alencar I, Bouzas L. Seleçaõ
Transplant. 2003;32(S1):S57–9. de doador de medula óssea ou de sangue periférico para o
134. Burt RK, Traynor A, Oyama Y, Craig R. High-dose immune transplante de células-tronco hematopoiéticas. In:
suppression and autologous hematopoietic stem cell Diretrizes da Sociedade Brasileira de Transplante de Medula
transplantation in refractory Crohn disease. Blood]. Óssea [Internet]. Sociedade Brasileira de Transplante de
2003;101(5):2064–6. Medula Óssea (SBTMO); 2012. p. 15–8. Available from:
135. Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, http://www.sbtmo.org.br/userfiles/fck/Diretrizes da
et al. Randomized controlled trials of autologous Sociedade Brasileira de Transplante de Medula Óssea 2012
hematopoietic stem cell transplantation for autoimmune ISBN 978-85-88902-17-6.pdf
diseases: the evolution from myeloablative to 149. Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R,
lymphoablative transplant regimens. Arthritis Rheum. et al. Autologous stem cell transplantation in refractory
2006;54(12):3750–60. Crohn’s disease – low intensity therapy evaluation
136. Cassinotti A, Annaloro C, Ardizzone S, Onida F, Volpe AD, (ASTIClite): study protocols for a multicentre, randomised
Clerici M, et al. Autologous haematopoietic stem cell controlled trial and observational follow up study. BMC
transplantation without CD34+ cell selection in refractory Gastroenterol. 2019;19(1):82.
Crohn’s disease. Gut. 2008;57(2):211–7.
137. Hommes DW, Duijvestein M, Zelinkova Z, Stokkers PCF, Ley
MH, Stoker J, et al. Long-term follow-up of autologous

Hematology, Transfusion and Cell Therapy: Review Article

Uploaded by

Copyright:

Available Formats

Hematology, Transfusion and Cell Therapy: Review Article

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Hematology, Transfusion and Cell Therapy: Review Article

Uploaded by

Copyright:

Available Formats

hematol transfus cell ther.

Hematology, Transfusion and Cell Therapy

A review of hematopoietic stem cell

Maria Carolina Oliveira a , Juliana Bernardes Elias a , Daniela Aparecida de Moraes a ,

(HSCT). The European Society for Blood and Marrow Trans-

immune system.10,14 The purpose of HSCT in autoimmune

hematol transfus cell ther. 2 0 2 1;4 3(1):65–86

hematol transfus cell ther. 2 0 2 1;4 3(1):65–86

Single-arm prospective study

hematol transfus cell ther. 2 0 2 1;4 3(1):65–86

hematol transfus cell ther. 2 0 2 1;4 3(1):65–86

hematol transfus cell ther. 2 0 2 1;4 3(1):65–86

hematol transfus cell ther. 2 0 2 1;4 3(1):65–86

hematol transfus cell ther. 2 0 2 1;4 3(1):65–86

hematol transfus cell ther. 2 0 2 1;4 3(1):65–86

hematol transfus cell ther. 2 0 2 1;4 3(1):65–86

hematol transfus cell ther. 2 0 2 1;4 3(1):65–86

You might also like